Published in J Virol on May 09, 2007
Unifying vertical and nonvertical evolution: a stochastic ARG-based framework. Syst Biol (2009) 2.40
The remarkable frequency of human immunodeficiency virus type 1 genetic recombination. Microbiol Mol Biol Rev (2009) 2.02
Why do RNA viruses recombine? Nat Rev Microbiol (2011) 2.02
Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proc Natl Acad Sci U S A (2011) 1.93
Structural determinants and mechanism of HIV-1 genome packaging. J Mol Biol (2011) 1.83
Recombination rate and selection strength in HIV intra-patient evolution. PLoS Comput Biol (2010) 1.73
The role of recombination in the emergence of a complex and dynamic HIV epidemic. Retrovirology (2010) 1.69
In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J Virol (2008) 1.45
Molecular mechanisms of recombination restriction in the envelope gene of the human immunodeficiency virus. PLoS Pathog (2009) 1.45
Identifying the important HIV-1 recombination breakpoints. PLoS Comput Biol (2008) 1.42
Within-host evolution of Burkholderia pseudomallei in four cases of acute melioidosis. PLoS Pathog (2010) 1.33
Topology of viral evolution. Proc Natl Acad Sci U S A (2013) 1.19
Current perspectives on HIV-1 antiretroviral drug resistance. Viruses (2014) 1.04
Intercompartmental recombination of HIV-1 contributes to env intrahost diversity and modulates viral tropism and sensitivity to entry inhibitors. J Virol (2011) 1.00
RNA structures facilitate recombination-mediated gene swapping in HIV-1. J Virol (2010) 0.99
Timing the emergence of resistance to anti-HIV drugs with large genetic barriers. PLoS Comput Biol (2009) 0.97
The evolution of HIV: inferences using phylogenetics. Mol Phylogenet Evol (2011) 0.94
Genetic characterization of an isolate of HIV type 1 AG recombinant form circulating in Siberia, Russia. Arch Virol (2012) 0.92
Accuracy estimation of foamy virus genome copying. Retrovirology (2009) 0.92
Evolution of foamy viruses: the most ancient of all retroviruses. Viruses (2013) 0.89
Genetic architecture of HIV-1 genes circulating in north India & their functional implications. Indian J Med Res (2011) 0.87
Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma viruses. Retrovirology (2008) 0.86
Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif protein. Viruses (2012) 0.85
Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses. J Virol (2013) 0.85
Productive homologous and non-homologous recombination of hepatitis C virus in cell culture. PLoS Pathog (2013) 0.83
Suboptimal provirus expression explains apparent nonrandom cell coinfection with HIV-1. J Virol (2012) 0.82
NMR detection of intermolecular interaction sites in the dimeric 5'-leader of the HIV-1 genome. Proc Natl Acad Sci U S A (2016) 0.81
Recombination-mediated changes in coreceptor usage confer an augmented pathogenic phenotype in a nonhuman primate model of HIV-1-induced AIDS. J Virol (2011) 0.79
T-RECs: rapid and large-scale detection of recombination events among different evolutionary lineages of viral genomes. BMC Bioinformatics (2017) 0.76
Impact of antiretroviral pressure on selection of primary human immunodeficiency virus type 1 envelope sequences in vitro. J Gen Virol (2013) 0.76
NMR Studies of the Structure and Function of the HIV-1 5'-Leader. Viruses (2016) 0.75
Serial evolutionary networks of within-patient HIV-1 sequences reveal patterns of evolution of X4 strains. BMC Syst Biol (2009) 0.75
HIV-1 leader RNA dimeric interface revealed by NMR. Proc Natl Acad Sci U S A (2016) 0.75
HIV-1 diversity after a class switch failure. AIDS Res Hum Retroviruses (2010) 0.75
Natural non-homologous recombination led to the emergence of a duplicated V3-NS5A region in HCV-1b strains associated with hepatocellular carcinoma. PLoS One (2017) 0.75
Driving HIV-1 into a Vulnerable Corner by Taking Advantage of Viral Adaptation and Evolution. Front Microbiol (2017) 0.75
Multiple genomic recombination events in the evolution of saffold cardiovirus. PLoS One (2013) 0.75
Characterization of primary isolates of HIV type 1 CRF28_BF, CRF29_BF, and unique BF recombinants circulating in São Paulo, Brazil. AIDS Res Hum Retroviruses (2012) 0.75
Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients. Retrovirology (2008) 0.75
Antiviral drug resistance as an adaptive process. Virus Evol (2016) 0.75
Number of infection events per cell during HIV-1 cell-free infection. Sci Rep (2017) 0.75
The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res (1997) 175.36
Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. Genetics (1989) 73.50
MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. Brief Bioinform (2004) 72.40
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97
DnaSP, DNA polymorphism analyses by the coalescent and other methods. Bioinformatics (2003) 32.63
Viral dynamics in human immunodeficiency virus type 1 infection. Nature (1995) 28.54
Hitchhiking under positive Darwinian selection. Genetics (2000) 14.72
Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol (1995) 9.02
Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol (2005) 7.91
DNA recombination during PCR. Nucleic Acids Res (1990) 7.73
Estimation of evolutionary distance between nucleotide sequences. Mol Biol Evol (1984) 5.39
Recombination: Multiply infected spleen cells in HIV patients. Nature (2002) 4.38
Dynamics of HIV-1 recombination in its natural target cells. Proc Natl Acad Sci U S A (2004) 4.37
Likelihood-based tests of topologies in phylogenetics. Syst Biol (2000) 4.34
Genotypic predictors of human immunodeficiency virus type 1 drug resistance. Proc Natl Acad Sci U S A (2006) 3.76
Genetic recombination of human immunodeficiency virus. J Virol (1989) 3.61
High rate of recombination throughout the human immunodeficiency virus type 1 genome. J Virol (2000) 3.09
Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis (2003) 2.92
Pervasive genomic recombination of HIV-1 in vivo. Genetics (2004) 2.79
Human immunodeficiency virus type 1 recombination: rate, fidelity, and putative hot spots. J Virol (2002) 2.50
Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc Natl Acad Sci U S A (1998) 2.23
Stimulation and suppression of PCR-mediated recombination. Nucleic Acids Res (1998) 2.17
Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. Proc Natl Acad Sci U S A (1996) 2.17
Nonrandom HIV-1 infection and double infection via direct and cell-mediated pathways. Proc Natl Acad Sci U S A (2004) 1.91
Update of the Drug Resistance Mutations in HIV-1: 2005. Top HIV Med (2005) 1.83
Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance. J Virol (1995) 1.80
Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients. J Virol (2006) 1.68
Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS (2004) 1.61
Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr (2004) 1.61
Recombination in HIV: an important viral evolutionary strategy. Emerg Infect Dis (1997) 1.59
Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency. J Virol (2004) 1.59
Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS (2004) 1.53
Human immunodeficiency virus type 1 genomic RNA sequences in the female genital tract and blood: compartmentalization and intrapatient recombination. J Virol (2005) 1.53
Human immunodeficiency virus type 1 genetic recombination is more frequent than that of Moloney murine leukemia virus despite similar template switching rates. J Virol (2003) 1.52
Selection for human immunodeficiency virus type 1 recombinants in a patient with rapid progression to AIDS. J Virol (2002) 1.50
Analysis of env sequence evolution in human immunodeficiency virus-infected patients receiving therapy with nonnucleoside reverse-transcriptase inhibitors. J Infect Dis (2000) 1.46
Dynamic copy choice: steady state between murine leukemia virus polymerase and polymerase-dependent RNase H activity determines frequency of in vivo template switching. Proc Natl Acad Sci U S A (2001) 1.44
Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. J Virol (2004) 1.37
HIV-1 subtyping using phylogenetic analysis of pol gene sequences. J Virol Methods (2001) 1.36
Mechanisms of nonrandom human immunodeficiency virus type 1 infection and double infection: preference in virus entry is important but is not the sole factor. J Virol (2005) 1.36
Possible involvement of cell fusion and viral recombination in generation of human immunodeficiency virus variants that display dual resistance to AZT and 3TC. J Gen Virol (1995) 1.31
Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission. Antivir Ther (2004) 1.26
Persistence of four related human immunodeficiency virus subtypes during the course of zidovudine therapy: relationship between virion RNA and proviral DNA. J Virol (1994) 1.25
Independent evolution of the env and pol genes of HIV-1 during zidovudine therapy. AIDS (1996) 1.24
Stochastic interplay between mutation and recombination during the acquisition of drug resistance mutations in human immunodeficiency virus type 1. J Virol (2005) 1.18
Differences in HIV-1 pol sequences from female genital tract and blood during antiretroviral therapy. J Acquir Immune Defic Syndr (2003) 1.10
Rapid, transient changes at the env locus of plasma human immunodeficiency virus type 1 populations during the emergence of protease inhibitor resistance. J Virol (1998) 1.10
Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples. J Infect Dis (2000) 1.09
HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombination. Antiviral Res (1997) 1.06
Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispecies. J Gen Virol (2000) 1.06
Stability of transmitted drug-resistant HIV-1 species. Curr Opin Infect Dis (2005) 1.02
Comparison of the genetic recombination rates of human immunodeficiency virus type 1 in macrophages and T cells. J Virol (2005) 0.98
Dissection of a circumscribed recombination hot spot in HIV-1 after a single infectious cycle. J Biol Chem (2005) 0.98
Effect of a protease inhibitor-induced genetic bottleneck on human immunodeficiency virus type 1 env gene populations. J Virol (2005) 0.96
Differential virus evolution in blood and genital tract of HIV-infected females: evidence for the involvement of drug and non-drug resistance-associated mutations. Virology (2004) 0.89
Random important alterations in HIV-1 viral quasispecies after antiviral treatment. Antivir Ther (1996) 0.88
Organised genome dynamics in the Escherichia coli species results in highly diverse adaptive paths. PLoS Genet (2009) 8.51
Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science (2003) 6.20
HIV drug resistance. N Engl J Med (2004) 5.52
Stress-induced mutagenesis in bacteria. Science (2003) 4.44
APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature (2005) 3.53
Genome expansion and gene loss in powdery mildew fungi reveal tradeoffs in extreme parasitism. Science (2010) 3.35
Selection versus demography: a multilocus investigation of the domestication process in maize. Mol Biol Evol (2004) 3.22
Extraintestinal virulence is a coincidental by-product of commensalism in B2 phylogenetic group Escherichia coli strains. Mol Biol Evol (2007) 2.44
Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther (2004) 2.14
Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog (2009) 2.06
Effector diversification within compartments of the Leptosphaeria maculans genome affected by Repeat-Induced Point mutations. Nat Commun (2011) 2.03
Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (2002) 2.03
Understanding the evolutionary fate of finite populations: the dynamics of mutational effects. PLoS Biol (2007) 1.95
Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr (2005) 1.80
Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients. J Virol (2006) 1.68
Mutation rate dynamics in a bacterial population reflect tension between adaptation and genetic load. Proc Natl Acad Sci U S A (2012) 1.56
Evolution of mutational robustness in an RNA virus. PLoS Biol (2005) 1.54
Mutation Rate Inferred From Synonymous Substitutions in a Long-Term Evolution Experiment With Escherichia coli. G3 (Bethesda) (2011) 1.53
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob Agents Chemother (2010) 1.53
Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure. J Clin Virol (2009) 1.51
Three-dimensional characterization of pathologic lesions in pulmonary langerhans cell histiocytosis. Am J Respir Crit Care Med (2002) 1.49
A unique virus release mechanism in the Archaea. Proc Natl Acad Sci U S A (2009) 1.47
Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors. J Virol (2003) 1.46
Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. J Virol (2004) 1.37
Role of intraspecies recombination in the spread of pathogenicity islands within the Escherichia coli species. PLoS Pathog (2009) 1.35
Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes. J Virol (2009) 1.30
Capturing the mutational landscape of the beta-lactamase TEM-1. Proc Natl Acad Sci U S A (2013) 1.28
Enhancement of the influenza A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase (NA). PLoS One (2009) 1.28
Animal and human pathogenic Escherichia coli strains share common genetic backgrounds. Infect Genet Evol (2011) 1.23
Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype. J Infect Dis (2002) 1.20
Evidence for a human-specific Escherichia coli clone. Environ Microbiol (2008) 1.19
Detection of extensive cross-neutralization between pandemic and seasonal A/H1N1 Influenza Viruses using a pseudotype neutralization assay. PLoS One (2010) 1.18
Molecular and evolutionary bases of within-patient genotypic and phenotypic diversity in Escherichia coli extraintestinal infections. PLoS Pathog (2010) 1.18
Alpha/beta interferon impairs the ability of human macrophages to control growth of Mycobacterium bovis BCG. Infect Immun (2002) 1.17
Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure. Antimicrob Agents Chemother (2009) 1.16
Large chromosomal rearrangements during a long-term evolution experiment with Escherichia coli. MBio (2014) 1.14
Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clin Pharmacol Ther (2004) 1.13
Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J Virol (2006) 1.13
The evolution of epistasis and its links with genetic robustness, complexity and drift in a phenotypic model of adaptation. Genetics (2009) 1.12
Epistasis and allele specificity in the emergence of a stable polymorphism in Escherichia coli. Science (2014) 1.10
Tempo and mode of genome evolution in a 50,000-generation experiment. Nature (2016) 1.10
Evolution of Escherichia coli rifampicin resistance in an antibiotic-free environment during thermal stress. BMC Evol Biol (2013) 1.09
Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients. Antimicrob Agents Chemother (2008) 1.09
Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France. J Antimicrob Chemother (2010) 1.09
Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations. AIDS (2003) 1.08
Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy. Antivir Ther (2006) 1.07
Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine. J Infect Dis (2013) 1.06
Intermediate mutation frequencies favor evolution of multidrug resistance in Escherichia coli. Genetics (2005) 1.05
Selection acts on DNA secondary structures to decrease transcriptional mutagenesis. PLoS Genet (2006) 1.04
G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not. Retrovirology (2011) 1.03
Mutation rate and genome reduction in endosymbiotic and free-living bacteria. Genetica (2007) 1.02
Functional central polypurine tract provides downstream protection of the human immunodeficiency virus type 1 genome from editing by APOBEC3G and APOBEC3B. J Virol (2006) 1.01
Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivity. J Virol (2005) 1.01
Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial. J Acquir Immune Defic Syndr (2012) 1.01
Productive HIV-1 infection of primary CD4+ T cells induces mitochondrial membrane permeabilization leading to a caspase-independent cell death. J Biol Chem (2001) 0.99
Gag cytotoxic T lymphocyte escape mutations can increase sensitivity of HIV-1 to human TRIM5alpha, linking intrinsic and acquired immunity. J Virol (2011) 0.99
Residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir of women treated with HAART: the prospective ANRS EP24 GYNODYN study. Antivir Ther (2011) 0.98
Human immunodeficiency virus type 1: resistance to nucleoside analogues and replicative capacity in primary human macrophages. J Virol (2007) 0.98
The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. J Antimicrob Chemother (2011) 0.98
Selection for chaperone-like mediated genetic robustness at low mutation rate: impact of drift, epistasis and complexity. Genetics (2009) 0.97
Complete nucleotide sequence of plasmid pTN48, encoding the CTX-M-14 extended-spectrum β-lactamase from an Escherichia coli O102-ST405 strain. Antimicrob Agents Chemother (2010) 0.97
A module located at a chromosomal integration hot spot is responsible for the multidrug resistance of a reference strain from Escherichia coli clonal group A. Antimicrob Agents Chemother (2009) 0.97
High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. Clin Infect Dis (2009) 0.96
Strain-specific differences in the impact of human TRIM5alpha, different TRIM5alpha alleles, and the inhibition of capsid-cyclophilin A interactions on the infectivity of HIV-1. J Virol (2010) 0.95
Modulation of HIV-1 infectivity and cyclophilin A-dependence by Gag sequence and target cell type. Retrovirology (2009) 0.94
High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations. J Acquir Immune Defic Syndr (2008) 0.93
Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial. Antivir Ther (2006) 0.93
Disruption of the gene homologous to mammalian Nramp1 in Mycobacterium tuberculosis does not affect virulence in mice. Infect Immun (2002) 0.93
Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J Med Virol (2004) 0.92
Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients. Antimicrob Agents Chemother (2009) 0.91
High rate of antiretroviral drug resistance mutations in HIV type 1-infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines. AIDS Res Hum Retroviruses (2012) 0.91
Bacteriophage PhiX174's ecological niche and the flexibility of its Escherichia coli lipopolysaccharide receptor. Appl Environ Microbiol (2010) 0.89
Properties of selected mutations and genotypic landscapes under Fisher's geometric model. Evolution (2014) 0.88
Impact of HIV-1 group O genetic diversity on genotypic resistance interpretation by algorithms designed for HIV-1 group M. J Acquir Immune Defic Syndr (2011) 0.87
Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir. Antimicrob Agents Chemother (2002) 0.87
Modulation of TRIM5alpha activity in human cells by alternatively spliced TRIM5 isoforms. J Virol (2011) 0.87
Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection. Retrovirology (2008) 0.87
Early archives of genetically-restricted proviral DNA in the female genital tract after heterosexual transmission of HIV-1. AIDS (2007) 0.87
Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma viruses. Retrovirology (2008) 0.86
Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide. Antimicrob Agents Chemother (2010) 0.86
Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure. Antivir Ther (2004) 0.86
Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues. J Virol (2005) 0.86